Linerixibat Long-term Safety, and Tolerability Study

Inclusion Criteria: * Male and female participants must be 18 to 80 years of age inclusive, at the time of signing the informed consent in the participant's parent trial BAT117213, GLIMMER or GLISTEN. * Participants with a diagnosis of PBC and a history of associated pruritus as evidenced by randomization into a prior eligible linerixibat clinical trial (BAT117213, GLIMMER or GLISTEN). * Participants must have completed the main treatment period in a prior eligible linerixibat clinical trial (BAT117213, GLIMMER or GLISTEN). * A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: a) is a woman of non-childbearing potential (WONCBP) or b) is a woman of childbearing potential (WOCBP) and using an acceptable contraceptive method. * Capable of giving signed informed consent. Exclusion Criteria: * Screening total bilirubin \>2x upper limit of normal (ULN). * Screening alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>6x ULN. * Screening estimated glomerular filtration rate (eGFR) \<30 milliliters per minute per 1.73 square meter (mL/min/1.73m\^2) based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. * Presence of hepatic decompensation (e.g., variceal bleeds, encephalopathy or ascites). * Presence of actively replicating viral hepatitis B or C (Viral Hepatitis B \[HBV\], viral Hepatitis C \[HCV\]) infection), primary sclerosing cholangitis (PSC), alcoholic liver disease and/or confirmed hepatocellular carcinoma or biliary cancer. * Current clinically significant diarrhea in the Investigator's medical opinion. * Current symptomatic cholelithiasis or cholecystitis. * Current diagnosis or previous diagnosis of colorectal cancer. * Any current malignancies (including hematologic and solid malignancies). * History of bariatric surgery with ileal bypass at any time, or any bariatric surgery performed in the past 3 years. * Use of Obeticholic acid: within 8 weeks prior to the date of the screening visit and may not restart until after the end of the study or early study withdrawal. * Administration of any other ileal bile acid transporter (IBAT) inhibitor in the 1 month prior to screening until after the end of the study or early study withdrawal. * QT interval corrected (QTc) \>480 millisecond (msec) at screening (12-lead ECG) * Participants with moderate (or greater) alcohol consumption defined as more than one standard drink per day for women and two drinks per day for men.